Skip to main content
Kringle Pharma,Inc. logo

Kringle Pharma,Inc. — Investor Relations & Filings

Ticker · 4884 ISIN · JP3270790003 T Manufacturing
Open in API
Filings indexed 53 across all filing types
Latest filing 2021-08-13 Interim / Quarterly Rep…
Country JP Japan
Listing T 4884

About Kringle Pharma,Inc.

https://www.kringle-pharma.com/en/

Kringle Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on the research and development of regenerative medicines for intractable and rare diseases. The company's core technology is based on recombinant human Hepatocyte Growth Factor (HGF), an endogenous protein with tissue-protective, regenerative, and repairing functions. Kringle Pharma has established a platform to manufacture pharmaceutical-grade HGF protein and is conducting clinical trials for several indications. Key development programs target conditions including acute spinal cord injury, vocal fold scarring, and Amyotrophic Lateral Sclerosis (ALS).

Recent filings

Filing Released Lang Actions
四半期報告書－第20期第3四半期(令和3年4月1日－令和3年6月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed under the Financial Instruments and Exchange Act of Japan. It contains detailed financial statements, including the balance sheet and income statement for the third quarter, and management's analysis of financial results. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2021
2021-08-13 Japanese
四半期報告書－第20期第2四半期(令和3年1月1日－令和3年3月31日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kinki Finance Bureau in Japan. It contains detailed financial statements, including the balance sheet and income statement, for the second quarter of the 20th fiscal period (ending March 31, 2021). It is a comprehensive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report (IR). H1 2021
2021-05-14 Japanese
四半期報告書－第20期第1四半期(令和2年10月1日－令和2年12月31日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kinki Finance Bureau in Japan. It contains detailed financial statements, including the balance sheet and income statement for the first quarter of the 20th fiscal period (October 1, 2020, to December 31, 2020). It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2020
2021-02-12 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, Article 24-4-2, Paragraph 1. This is a standard Japanese regulatory filing that accompanies an Annual Securities Report (Yukashoken Hokokusho) to confirm the accuracy of the report's contents. Since it is a specific regulatory filing required by law and does not fit into the other categories like 10-K or IR, it is classified as a Regulatory Filing (RNS). FY 2020
2020-12-28 Japanese
有価証券報告書－第19期(令和1年10月1日－令和2年9月30日)
Annual Report Classification · 100% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which translates to 'Annual Securities Report'. This is the standard Japanese regulatory filing equivalent to the US 10-K, containing comprehensive financial statements, business descriptions, and management analysis for the fiscal year. It is a formal, long-form document submitted to the Kanto Local Finance Bureau, fitting the definition of an Annual Report (10-K). FY 2020
2020-12-28 Japanese
訂正有価証券届出書（新規公開時）
Share Issue/Capital Change Classification · 98% confidence The document is a 'Securities Registration Statement' (有価証券届出書) filed with the Kinki Finance Bureau in Japan. It details the offering of new shares, book-building procedures, underwriting agreements, and capital structure changes for Kringle Pharma, Inc. in preparation for an IPO on the Tokyo Stock Exchange Mothers market. This document type is a standard regulatory filing for capital raising and public offerings, which falls under the 'Share Issue/Capital Change' category as it specifically outlines the issuance of new shares and capital structure adjustments.
2020-12-17 Japanese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.